Altium Capital Management LLC Takes $2.67 Million Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Altium Capital Management LLC bought a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 405,000 shares of the company's stock, valued at approximately $2,665,000. Altium Capital Management LLC owned 1.22% of Lexeo Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Lexeo Therapeutics by 86.5% in the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company's stock valued at $5,003,000 after buying an additional 256,635 shares in the last quarter. Privium Fund Management B.V. bought a new position in Lexeo Therapeutics during the fourth quarter worth about $909,000. ADAR1 Capital Management LLC boosted its holdings in Lexeo Therapeutics by 196.5% during the fourth quarter. ADAR1 Capital Management LLC now owns 169,505 shares of the company's stock valued at $1,115,000 after purchasing an additional 112,339 shares in the last quarter. Exome Asset Management LLC bought a new stake in shares of Lexeo Therapeutics in the 3rd quarter valued at approximately $797,000. Finally, Walleye Capital LLC acquired a new position in shares of Lexeo Therapeutics in the 4th quarter worth approximately $407,000. Institutional investors and hedge funds own 60.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Leerink Partners lowered their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Monday, March 24th. Chardan Capital lowered their target price on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a report on Tuesday, April 8th. Royal Bank of Canada cut their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $22.20.

Lexeo Therapeutics Stock Down 0.6 %

LXEO traded down $0.02 during trading on Wednesday, hitting $3.40. The company had a trading volume of 346,388 shares, compared to its average volume of 416,992. The company has a market capitalization of $112.87 million, a PE ratio of -1.08 and a beta of 1.52. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics, Inc. has a one year low of $1.45 and a one year high of $19.50. The firm's 50-day moving average price is $3.04 and its 200 day moving average price is $5.67.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09. As a group, equities analysts expect that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.